PepGen Inc.

PepGen Inc. reported a reduced net loss of $17.8 million for the second quarter of 2026, an improvement from $23.1 million in the same period last year. For the six months ended June 30, 2026, the net loss also decreased to $35.6 million from $53.3 million year-over-year. The clinical-stage biotechnology company ended the quarter with $117.2 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations for at least the next 12 months. The company continues to incur significant operating losses and expects to raise additional funding.

PepGen Inc. updated its Corporate Presentation for the 15th International Myotonic Dystrophy Consortium, highlighting promising clinical data for PGN-EDODM1 in Myotonic Dystrophy Type 1 (DM1). The FREEDOM single-ascending dose study demonstrated dose-dependent splicing correction, with 87.5% of participants showing improvement. The FREEDOM2 multiple-ascending dose 5 mg/kg cohort showed a favorable safety profile and mean splicing correction of 7.3%, with promising vHOT trends. The company anticipates reporting 10 mg/kg clinical results in 2H 2026 and 12.5 mg/kg results in 2027, supported by a cash runway into 2H 2027.

PepGen Inc. reported a net loss of $17.8 million, or $(0.26) per share, for Q1 2026, a significant reduction from $30.2 million in Q1 2025. The company also announced favorable safety and efficacy data from the 5 mg/kg cohort of its PGN-EDODM1 FREEDOM2 trial for DM1, with the 10 mg/kg cohort fully enrolled and data expected in 2H 2026. Despite a partial clinical hold by the FDA on the FREEDOM2 study, PepGen stated the timing of the ongoing trial remains unaffected and its $132.3 million cash balance provides funding into 2H 2027.

PepGen Inc. reported a narrowed net loss of $17.8 million for the first quarter of 2026, a significant improvement from the $30.2 million loss in the prior year, primarily driven by a 48.7% reduction in research and development expenses. The company's cash, cash equivalents, and marketable securities stood at $132.3 million as of March 31, 2026, which is expected to fund operations for at least the next 12 months. Additionally, the board approved a stock option repricing in November 2025 for eligible employees, setting a new exercise price of $4.53.

PepGen Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 18, 2026, at 12:00 p.m. Eastern Daylight Time. Stockholders of record as of April 21, 2026, are invited to vote on the election of three Class I directors and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company is utilizing the Notice of Internet Availability of Proxy Materials to provide access to proxy materials online.